Sung H, Ferlay J, Siegel RL et al. 2020 global cancer statistics: GLOBOCAN estimates worldwide morbidity and mortality rates for 36 cancers in 185 countries. CA Cancer J Clinic. 2021;71:209–49.
Google Scholar
Adjani JA, D’Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2022, NCCN Oncology Clinical Practice Guidelines. J Natl Compr Canc Netw 2022;20:167–192.
Fuchs CS, Tomasek J, Yong CJ et al Ramucirumab monotherapy (REGARD) for previously treated advanced gastric cancer or gastroesophageal junction adenocarcinoma: an international, randomized, multicenter, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9.
Google Scholar
Wilke H, Muro K, Van Cutsem E Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric cancer or gastroesophageal junction adenocarcinoma (RAINBOW): A double-masked, randomized, phase 3 trial. Lancet Oncor. 2014;15:1224–35.
Google Scholar
Xu RH, Zhang Y, Pan H et al. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomized, multicenter, double-masked, phase 3 trial. Lancet Gastrointestinal Roll Hepatol. 2021;6:1015–24.
Google Scholar
Van Cutsem E, Muro K, Cunningham D, et al Biomarker analysis of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global randomized, double-blind phase 3 trial. Euro J Cancer. 2020;127:150–7.
Google Scholar
Masato Natsume, Takuya Shimura, Hiroshi Iwasaki, et al. Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer. Cancer chemotherapy drug. 2019;83:1037–46.
Google Scholar
Aprile G, Ongaro E, Del Re M et al. Angiogenesis inhibitors in gastric and gastroesophageal junction cancers: key insights. Critical Rev Oncor Hematol. 2015;95:165–78.
Google Scholar
Shigeyasu K, Torden S, Zumwalt TJ et al. Emerging role of MicroRNA as liquid biopsy biomarker in gastrointestinal cancer. Clinical Cancer Research Institute 2017;23(10):2391–9.
Google Scholar
Yu W, Hurley J, Roberts D. Exosome-based liquid biopsy in other cancers: opportunities and challenges. Ann Oncol. 2021;32:466–77.
Google Scholar
Tang XH, Guo T, Gao XY et al. Exosome-derived non-coding RNA in gastric cancer: functions and clinical applications. Morgan. 2021;20:99.
Google Scholar
Huang T, Song C, Zheng L, et al. Role of extracellular vesicles in gastric cancer development, microenvironment, anticancer drug resistance, and treatment. Morgan. 2019;18:62.
Google Scholar
Carli R, Lebroux VS. Biology, function, and biomedical applications of exosomes. Science. 2020. https://doi.org/10.1126/science.aau6977.
Google Scholar
Hiroshi Tanioka, Tetsu Nagasaka, Aya Uno et al. Relationship between peripheral neuropathy and the efficacy of second-line chemotherapy for unresectable advanced gastric cancer: Prospective observational multicenter study protocol (IVY). BMC cancer. 2019;19:941.
Google Scholar
Kazuya Shitara, Aki Takashima, Kazuya Fujitani, et al. Comparison of Nab-paclitaxel and vehicle-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomized, non-inferiority, phase 3 study. Lancet Gastroenterology and Hepatology. 2017;2:277–87.
Google Scholar
Hiroshi Bando, Hiroshi Shimohira, Kazuto Fujitani, et al.A phase II study of the combination of nab-paclitaxel and ramucirumab in patients with advanced gastric cancer who had received prior treatment. Euro J Cancer. 2018;91:86–91.
Google Scholar
Kazuya Okuno, Tetsuya Watanabe, Roy S, et al. Liquid biopsy signature for predicting early recurrence in gastric cancer patients. Br J Cancer. 2023;128:1105–16.
Google Scholar
Kazuto Okuno, Masaki Tokunaga, Yuya Kinugasa, Transcriptome liquid biopsy assay for predicting resistance to neoadjuvant therapy in other esophageal squamous cell carcinomas. Anne Sarg. 2022;276:101–10.
Google Scholar
Eisenhauer EA, Sellasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guidelines (version 1.1). Euro J Cancer. 2009;45:228–47.
Google Scholar
Fan Y, Shiklenka K, Arora SK, et al. Mirnet – Dissecting miRNA-target interactions and functional associations through network-based visual analysis. Nucleic Acid Research Institute 2016;44:W135–41.
Google Scholar
Women’s SS, Badgewell BD. Current treatments and recent advances in gastric cancer. CA Cancer J Clinic. 2021;71:264–79.
Google Scholar
Alsina M, Arazbi V, Diez M, et al. Current developments in gastric cancer: from molecular profiling to therapeutic strategies. Nat Rev Gastrointestinal Roll Hepatol. 2023;20:155–70.
Google Scholar
Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced/recurrent gastric or gastroesophageal junction cancer (ATTRACTION-4): A randomized, multicenter, double-blind, placebo-controlled, phase 3 study. Lancet Oncor. 2022;23:234–47.
Google Scholar
Shitara K, Van Cutsem E, Bang YJ et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy versus chemotherapy alone for patients with first-line advanced gastric cancer: KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncor. 2020;6:1571–80.
Google Scholar
Tetsuya Hironaka, Tetsuya Ueda, Hiroshi Yasui, et al. A randomized, open-label, phase III study comparing irinotecan and paclitaxel in patients with advanced gastric cancer without severe peritoneal metastases who have failed prior combination chemotherapy using fluoropyrimidine and platinum: WJOG 4007 study. J Clin Oncol. 2013;31:4438–44.
Google Scholar
Kazuya Shitara, Tetsuya Doi, Dvorkin M, et al. Comparison of trifluridine/tipiracil versus placebo in heavily pretreated patients with metastatic gastric cancer (TAGS): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet Oncor. 2018;19:1437–48.
Google Scholar
Kazuya Shitara, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan for previously treated HER2-positive gastric cancer. N Eng J Med 2020;382:2419–30.
Google Scholar
Fornaro L, Musettini G, Orlandi P, et al. Early increases in plasma soluble VEGFR-2 are associated with clinical benefit from second-line treatment with paclitaxel and ramucirumab in advanced gastric cancer. J Cancer Research Institute. 2022;12:3347–56.
Google Scholar
Sundar R, Barr Kumarakulasinghe N, Huak Chan Y, et al. Machine learning model-derived genetic signature predicting survival benefit of paclitaxel in gastric cancer: Results from the randomized phase III SAMIT trial. Intestines. 2022;71:676–85.
Google Scholar
Hou J, Zhuo H, Chen X et al. Mir-139-5p negatively regulates PMP22 and suppresses cell proliferation by targeting the NF-κB signaling pathway in gastric cancer. Int J Biol Sci. 2020;16:1218–29.
Google Scholar
Zhao YJ, Zhang J, Wang YC et al. MiR-450a-5p inhibits the proliferation, migration, and invasion of gastric cancer cells and promotes apoptosis by targeting CREB1 and inhibiting the AKT/GSK-3β signaling pathway. Front on col. 2021;11:633366.
Google Scholar
Meng Q, Tan S, Jiang Y et al Post-discharge oral nutritional supplements with dietary advice for patients at nutritional risk after gastric cancer surgery: a randomized clinical trial. Clin Natl. 2021;40:40–6.
Google Scholar
Takuya Kawamura, Takashi Makuuchi, Masato Tokunaga, Long-term outcomes of gastric cancer patients with preoperative sarcopenia. Ann saag oncol. 2018;25:1625–32.
Google Scholar
Hideto Kamiya, S Komatsu, Kazuya Nishibeppu, et al. Obesity paradox as new insight gained from postoperative complications of gastric cancer. Sci Rep. 2023;13:10116.
Google Scholar
Buschmann D, Kirchner B, Hellmann S, et al. Evaluation of serum extracellular vesicle isolation methods for miRNA profiling by next-generation sequencing. J Extracellular vesicles. 2018;7:1481321.
Google Scholar
Llorens-Rebre M, Martínez-González B, Kuell J, Esteban JI, et al. Comparison of extracellular vesicle isolation methods for miRNA sequencing. Int J Mol Sci. 2023;24:12183.
Google Scholar
Piccinno E, Schirizzi A, Scalavino V et al. Circulating miR-23b-3p, miR-30e-3p, and miR-205-5p as novel predictive biomarkers of outcome of ramucirumab-paclitaxel therapy in advanced gastric cancer. Int J Mol Sci. 2024;25:13498.
Google Scholar
